Over the latest trailing 12-month period, total return cagr is +253.76%. The comparable SPY value is +16.94%. Year-to-date total return is +183.31%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Total Return CAGR averages 25.31% over 3 years; the trailing 12 months came in at +253.76%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
Nuvectis Pharma, Inc. (NVCT)
Total Return growth vs the same calendar quarter one year earlier, last 16 comparable quarters.
Quarter-end value of $100 invested at the start of the available history, with dividends reinvested; the newest quarter may be quarter-to-date. Q4 2026 (2026-10-05): $658.15.
| Year | Total return for the year |
|---|---|
| 2026 (YTD) | +183.31% |
| 2025 | +39.56% |
| 2024 | -35.13% |
| 2023 | +11.20% |
| Period | Period End | QoQ Return | YoY Return |
|---|---|---|---|
| Q4 2026 (QTD) | 2026-10-05 | +1.3% | +189.8% |
| Q3 2026 | 2026-09-30 | +14.8% | +256.8% |
| Q2 2026 | 2026-06-30 | +137.9% | +143.6% |
| Q1 2026 | 2026-03-31 | +4.7% | -26.1% |
| Q4 2025 | 2025-12-30 | +24.7% | +43.6% |
| Q3 2025 | 2025-09-29 | -21.6% | -4.2% |
| Q2 2025 | 2025-06-27 | -27.8% | +20.4% |
| Q1 2025 | 2025-03-28 | +103.5% | +27.6% |
| Q4 2024 | 2024-12-30 | -16.8% | -40.0% |
| Q3 2024 | 2024-09-27 | -1.4% | -52.1% |
| Q2 2024 | 2024-06-27 | -23.5% | -61.6% |
| Q1 2024 | 2024-03-28 | -4.3% | -34.0% |
| Q4 2023 | 2023-12-28 | -33.5% | +15.5% |
| Q3 2023 | 2023-09-29 | -21.1% | +81.8% |
| Q2 2023 | 2023-06-29 | +31.5% | +45.9% |
| Q1 2023 | 2023-03-30 | +67.5% | +67.7% |
Calendar returns: QoQ compares the prior calendar quarter; YoY compares the same calendar quarter a year earlier. The newest quarter is in progress (quarter-to-date).
